2026 Q2 -tulosraportti
8 päivää sitten
‧1 t 2 min
0,4074 USD/osake
Irtoamispäivä 17.8.
2,61%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·20 t sitten · MuokattuI really can't understand why there isn't more focus on Awiqli and that it's now being sold in the USA.. It seems like everything is now about fat percentages.. I asked AI: Awiqli from Novo Nordisk is the world's first weekly basal insulin. The active substance in the medicine is called insulin icodec. The drug is designed to replace traditional long-acting insulins, which patients normally have to inject themselves with every single day. Important details about Awiqli. Fewer injections: With the new drug, the number of annual insulin injections is significantly reduced from 365 to 52 injections per year. Target group: It is primarily approved for adults with type 2 diabetes. For type 1 diabetes, it must always be combined with rapid-acting mealtime insulin. Effect: The insulin is released slowly and steadily into the body over seven days because the molecule binds to the protein albumin in the blood.
·5.8.I bought NN for 44,02 dollar - 285 DK last night now we'll have to see if it was a good idea?
Eli Lilly has been a better business since February 5th this year compared to Novo, even though Novo is ahead today. Over 5 years, EL takes off completely, but over the total period they have both been on the stock exchange, it is Novo that has risen the most, actually 5-6 x so much better than EL.
·4.8.The strategy of issuing cautious guidance has proven to be completely wrong They dropped 17% in Feb. Now they are dropping 6-8 % by saying that the result will be approximately the same as last year Between the two announcements, they dropped 17% on Cagrisema and 7% the other day They simply have to appear more optimistic - it's a true nightmare to be involved here - like a prison
·4.8.Exciting, and perhaps not entirely unexpected price reaction - now a very large player is shaking the tree one last time and on stock forums all over the world, bots and paid writers are complaining about the price drop in Novo. Superficially, it's obviously sad that such a good report is met with a significant downturn, but once the initial panic subsides, we know that Novo is turning the ship around AND that both Ozempic and Wegovy are selling better than expected. Who the big player acting today is, I don't know, but Blackrock has significantly increased its stake in Novo since Novo's downturn began - and the heavily biased answers one gets when searching for info about Blackrock's holdings in Novo Nordisk, I think, point to Blackrock being more than happy to further increase its ownership stake in Novo. All in all, it means buying more Novo tomorrow, because this downturn will never last over time.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
8 päivää sitten
‧1 t 2 min
0,4074 USD/osake
Irtoamispäivä 17.8.
2,61%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·20 t sitten · MuokattuI really can't understand why there isn't more focus on Awiqli and that it's now being sold in the USA.. It seems like everything is now about fat percentages.. I asked AI: Awiqli from Novo Nordisk is the world's first weekly basal insulin. The active substance in the medicine is called insulin icodec. The drug is designed to replace traditional long-acting insulins, which patients normally have to inject themselves with every single day. Important details about Awiqli. Fewer injections: With the new drug, the number of annual insulin injections is significantly reduced from 365 to 52 injections per year. Target group: It is primarily approved for adults with type 2 diabetes. For type 1 diabetes, it must always be combined with rapid-acting mealtime insulin. Effect: The insulin is released slowly and steadily into the body over seven days because the molecule binds to the protein albumin in the blood.
- ·5.8.I bought NN for 44,02 dollar - 285 DK last night now we'll have to see if it was a good idea?Eli Lilly has been a better business since February 5th this year compared to Novo, even though Novo is ahead today. Over 5 years, EL takes off completely, but over the total period they have both been on the stock exchange, it is Novo that has risen the most, actually 5-6 x so much better than EL.
- ·4.8.The strategy of issuing cautious guidance has proven to be completely wrong They dropped 17% in Feb. Now they are dropping 6-8 % by saying that the result will be approximately the same as last year Between the two announcements, they dropped 17% on Cagrisema and 7% the other day They simply have to appear more optimistic - it's a true nightmare to be involved here - like a prison
- ·4.8.Exciting, and perhaps not entirely unexpected price reaction - now a very large player is shaking the tree one last time and on stock forums all over the world, bots and paid writers are complaining about the price drop in Novo. Superficially, it's obviously sad that such a good report is met with a significant downturn, but once the initial panic subsides, we know that Novo is turning the ship around AND that both Ozempic and Wegovy are selling better than expected. Who the big player acting today is, I don't know, but Blackrock has significantly increased its stake in Novo since Novo's downturn began - and the heavily biased answers one gets when searching for info about Blackrock's holdings in Novo Nordisk, I think, point to Blackrock being more than happy to further increase its ownership stake in Novo. All in all, it means buying more Novo tomorrow, because this downturn will never last over time.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
2026 Q2 -tulosraportti
8 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
0,4074 USD/osake
Irtoamispäivä 17.8.
2,61%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·20 t sitten · MuokattuI really can't understand why there isn't more focus on Awiqli and that it's now being sold in the USA.. It seems like everything is now about fat percentages.. I asked AI: Awiqli from Novo Nordisk is the world's first weekly basal insulin. The active substance in the medicine is called insulin icodec. The drug is designed to replace traditional long-acting insulins, which patients normally have to inject themselves with every single day. Important details about Awiqli. Fewer injections: With the new drug, the number of annual insulin injections is significantly reduced from 365 to 52 injections per year. Target group: It is primarily approved for adults with type 2 diabetes. For type 1 diabetes, it must always be combined with rapid-acting mealtime insulin. Effect: The insulin is released slowly and steadily into the body over seven days because the molecule binds to the protein albumin in the blood.
- ·5.8.I bought NN for 44,02 dollar - 285 DK last night now we'll have to see if it was a good idea?Eli Lilly has been a better business since February 5th this year compared to Novo, even though Novo is ahead today. Over 5 years, EL takes off completely, but over the total period they have both been on the stock exchange, it is Novo that has risen the most, actually 5-6 x so much better than EL.
- ·4.8.The strategy of issuing cautious guidance has proven to be completely wrong They dropped 17% in Feb. Now they are dropping 6-8 % by saying that the result will be approximately the same as last year Between the two announcements, they dropped 17% on Cagrisema and 7% the other day They simply have to appear more optimistic - it's a true nightmare to be involved here - like a prison
- ·4.8.Exciting, and perhaps not entirely unexpected price reaction - now a very large player is shaking the tree one last time and on stock forums all over the world, bots and paid writers are complaining about the price drop in Novo. Superficially, it's obviously sad that such a good report is met with a significant downturn, but once the initial panic subsides, we know that Novo is turning the ship around AND that both Ozempic and Wegovy are selling better than expected. Who the big player acting today is, I don't know, but Blackrock has significantly increased its stake in Novo since Novo's downturn began - and the heavily biased answers one gets when searching for info about Blackrock's holdings in Novo Nordisk, I think, point to Blackrock being more than happy to further increase its ownership stake in Novo. All in all, it means buying more Novo tomorrow, because this downturn will never last over time.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt